Skip to content
PubMed This is a summary of 16 peer-reviewed journal articles Updated
Genetics

Understanding Your Child's CDG Diagnosis

At a Glance

Congenital Disorders of Glycosylation (CDG) are rare genetic diseases that prevent the body from properly attaching sugar chains to proteins. This biological glitch affects multiple organs. While mostly treated with supportive multidisciplinary care, research is rapidly advancing new therapies.

Receiving a diagnosis of a Congenital Disorder of Glycosylation (CDG) can feel like being dropped into a world where no one speaks the language. You may find that even your pediatrician or local hospital staff have never heard of it. This is a common experience with rare diseases, but please know that while your child’s condition is rare, you are entering a global community of families and experts dedicated to understanding and treating these disorders [1][2].

Understanding the “Barcode” of Life

To understand CDG, it helps to understand glycosylation. Think of it as a biological “finishing school” for the proteins and fats in your child’s body.

  • The Process: Every cell in the body makes proteins to perform jobs like building muscle or fighting infection. Before these proteins can go to work, the body must attach “sugar chains” (glycans) to them [3][4].
  • The Barcode: These sugar chains act like a barcode or shipping label. They tell the protein where to go in the body and how to do its job correctly [3].
  • The Defect: In CDG, a genetic “glitch” prevents the body from attaching these sugar labels correctly. Because proteins are used in almost every organ, this “glitch” can affect many different parts of the body at once, including the brain, liver, heart, and immune system [5][6].

How Rare is CDG?

There are over 160 different types of CDG identified so far, and new ones are discovered every year [7]. While some types, like PMM2-CDG, are more common, many others are “ultra-rare,” meaning only a handful of children in the world have them [8][9].

Because it is so rare, your local doctors may not have the specialized knowledge needed for long-term management. This is why multidisciplinary care—a team of different specialists working together—is the gold standard for CDG [10]. This team often includes experts in genetics, metabolism, neurology, and gastroenterology [6][11].

Three Stabilizing Facts for Families

When everything feels uncertain, these three truths can serve as your foundation:

  1. A Diagnosis is a Map, Not a Destiny: While CDG is a lifelong condition, the diagnosis finally gives you a name for what your child is experiencing. This allows doctors to move from “searching” to “monitoring and managing.” Symptoms vary widely even between children with the same type of CDG, and many children have happy, social, and engaged lives [12].
  2. You Are Not Alone in This: There is a robust global network of researchers and patient advocacy groups (such as CDG CARE and the World CDG Organization). These groups connect families with the world’s leading experts, ensuring your child can benefit from the most current knowledge, even if you live far from a major medical center [2][13].
  3. Research is Accelerating: We are currently in an era of rapid discovery for CDG. Advanced genetic sequencing and new technologies like mass spectrometry (a highly sensitive way to look at sugar patterns) are leading to faster diagnoses and the development of targeted therapies for specific subtypes [14][15].

What to Expect Next

Management for CDG is generally supportive care. This means doctors focus on treating the symptoms and preventing complications rather than fixing the underlying genetic cause [6]. This may include:

  • Physical, occupational, and speech therapies to support development [13].
  • Regular monitoring of liver and heart function [6].
  • In some rare cases, specific sugar supplements (like mannose or fucose) that may bypass the genetic “glitch” [15][16].

Your role as a parent is not to become a scientist overnight, but to be the expert on your child and the coordinator of their care team [13].

You can read more about what symptoms to expect in the Signs and Symptoms section.

Common questions in this guide

What is a Congenital Disorder of Glycosylation (CDG)?
CDG is a rare genetic condition where the body cannot properly attach sugar chains to proteins and fats. Because these proteins need their "sugar barcodes" to function correctly, CDG can affect multiple organs at once, including the brain, liver, and heart.
How many types of CDG are there?
Researchers have identified over 160 different types of CDG, with new ones discovered regularly. While some types like PMM2-CDG are more common, many are considered ultra-rare and only affect a small number of children worldwide.
What kind of doctors should be on my child's CDG care team?
Because CDG affects multiple body systems, children do best with a multidisciplinary care team. This typically involves specialized doctors in genetics, metabolism, neurology, and gastroenterology, alongside various developmental therapists.
Are there specific treatments or cures for CDG?
Currently, treatment focuses heavily on supportive care like physical therapy, symptom management, and regular screening of organ function. However, in some rare cases, specialized sugar supplements like mannose or fucose can help bypass the specific genetic defect.
What is the long-term outlook for a child with CDG?
While CDG is a lifelong condition, the severity of symptoms varies widely even among children with the exact same genetic subtype. With proper supportive care and therapies, many children with CDG live happy, social, and engaged lives.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What is the specific genetic subtype of my child's CDG (e.g., PMM2-CDG), and how many other cases are known?
  2. 2.Which body systems (liver, heart, brain) are currently affected, and what screening schedule do you recommend to monitor them?
  3. 3.Are there any specialized metabolic centers or CDG experts you can consult with regarding my child's care?
  4. 4.Are there any specific supplements or clinical trials currently available for my child's subtype?
  5. 5.Can you help me coordinate a multidisciplinary team including specialists like neurologists, gastroenterologists, and therapists?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (16)
  1. 1

    Resilience in patients and family caregivers living with congenital disorders of glycosylation (CDG): a quantitative study using the brief resilience coping scale (BRCS).

    Poejo J, Gomes AI, Granjo P, Dos Reis Ferreira V

    Orphanet journal of rare diseases 2024; (19(1)):98 doi:10.1186/s13023-024-03043-x.

    PMID: 38439013
  2. 2

    Stakeholders' views on drug development: the congenital disorders of glycosylation community perspective.

    Monticelli M, Francisco R, Brasil S, et al.

    Orphanet journal of rare diseases 2022; (17(1)):303 doi:10.1186/s13023-022-02460-0.

    PMID: 35907899
  3. 3

    Protein glycosylation in cardiovascular health and disease.

    Chatham JC, Patel RP

    Nature reviews. Cardiology 2024; (21(8)):525-544 doi:10.1038/s41569-024-00998-z.

    PMID: 38499867
  4. 4

    Impact of N-Glycosylation on Protein Structure and Dynamics Linked to Enzymatic C-H Activation in the M. oryzae Lipoxygenase.

    Whittington C, Sharma A, Hill SG, et al.

    Biochemistry 2024; (63(10)):1335-1346 doi:10.1021/acs.biochem.4c00109.

    PMID: 38690768
  5. 5

    Complex Phenotypes in Inborn Errors of Metabolism: Overlapping Presentations in Congenital Disorders of Glycosylation and Mitochondrial Disorders.

    Gardeitchik T, Wyckmans J, Morava E

    Pediatric clinics of North America 2018; (65(2)):375-388 doi:10.1016/j.pcl.2017.11.012.

    PMID: 29502919
  6. 6

    Hyperkinetic movement disorders: expanding the phenotype of congenital disorders of glycosylation.

    Pandey S, Chouksey A

    European journal of neurology 2019; (26(9)):1141-1142 doi:10.1111/ene.14013.

    PMID: 31206957
  7. 7

    Matrix-Assisted Laser Desorption/Ionization Mass Spectrometry to Detect Diagnostic Glycopeptide Markers of Congenital Disorders of Glycosylation.

    Wada Y

    Mass spectrometry (Tokyo, Japan) 2020; (9(1)):A0084 doi:10.5702/massspectrometry.A0084.

    PMID: 32547898
  8. 8

    Hypoglycemia in CDG patients due to PMM2 mutations: Follow up on hyperinsulinemic patients.

    Moravej H, Altassan R, Jaeken J, et al.

    JIMD reports 2020; (51(1)):76-81 doi:10.1002/jmd2.12085.

    PMID: 32071842
  9. 9

    Ten years of screening for congenital disorders of glycosylation in Argentina: case studies and pitfalls.

    Asteggiano CG, Papazoglu M, Bistué Millón MB, et al.

    Pediatric research 2018; (84(6)):837-841 doi:10.1038/s41390-018-0206-6.

    PMID: 30397276
  10. 10

    Congenital disorder of glycosylation type IIb in an infant with developmental and epileptic encephalopathy.

    Shwetabh RK, Singh A, Mandal K, et al.

    BMJ case reports 2025; (18(11)) doi:10.1136/bcr-2025-268902.

    PMID: 41192964
  11. 11

    International clinical guidelines for the management of phosphomannomutase 2-congenital disorders of glycosylation: Diagnosis, treatment and follow up.

    Altassan R, Péanne R, Jaeken J, et al.

    Journal of inherited metabolic disease 2019; (42(1)):5-28 doi:10.1002/jimd.12024.

    PMID: 30740725
  12. 12

    Genetic counseling for congenital disorders of glycosylation (CDG).

    Weixel T, Wolfe L, Macnamara EF

    Journal of genetic counseling 2024; (33(6)):1358-1364 doi:10.1002/jgc4.1856.

    PMID: 38240170
  13. 13

    Experiences of parents with children with congenital disorders of glycosylation: What can we learn from them?

    Cardão C, Barros L, Francisco R, et al.

    Disability and health journal 2021; (14(3)):101065 doi:10.1016/j.dhjo.2021.101065.

    PMID: 33531289
  14. 14

    Advancement in Clinical Glycomics and Glycoproteomics for Congenital Disorders of Glycosylation: Progress and Challenges Ahead.

    Abu Bakar N, Hamzan NI

    Biomedicines 2025; (13(8)) doi:10.3390/biomedicines13081964.

    PMID: 40868218
  15. 15

    Liposome-encapsulated mannose-1-phosphate therapy improves global N-glycosylation in different congenital disorders of glycosylation.

    Budhraja R, Radenkovic S, Jain A, et al.

    Molecular genetics and metabolism 2024; (142(2)):108487 doi:10.1016/j.ymgme.2024.108487.

    PMID: 38733638
  16. 16

    A spoonful of L-fucose-an efficient therapy for GFUS-CDG, a new glycosylation disorder.

    Feichtinger RG, Hüllen A, Koller A, et al.

    EMBO molecular medicine 2021; (13(9)):e14332 doi:10.15252/emmm.202114332.

    PMID: 34468083

This page provides educational information about Congenital Disorders of Glycosylation (CDG) for families. It is not medical advice; please consult a geneticist or metabolic specialist for your child's specific care and screening needs.

Get notified when new evidence is published on Congenital disorder of glycosylation.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.